一种促黄体生成素释放激素激动剂（ICI 118.630，戈舍瑞林）治疗前列腺癌的临床研究。
Clinical study of an LH-RH agonist (ICI 118.630, Zoladex) in the treatment of prostatic cancer.
作者信息
Mauriac L, Coste P, Richaud P, Lamarche P, Mage P, Bonichon F
机构信息
Department of Clinical Oncology, Fondation Bergonie, Bordeaux, France.
出版信息
Am J Clin Oncol. 1988;11 Suppl 2:S117-9. doi: 10.1097/00000421-198801102-00029.
Eighty patients with prostatic cancer have been treated with an LH-RH analogue (Zoladex). Ten had no metastasis, and hormone therapy was used as an induction treatment before curative radiotherapy. The others had metastatic disease and, in some cases, had already received some form of endocrine therapy. Patients received a monthly injection of Zoladex (3.6 mg). No progressive disease was noted among patients with nonmetastatic tumors; of the patients with metastases, those who were previously untreated had a higher response rate (14.8% complete response) and longer progression-free and overall survival. Toxicity was mild in spite of two cases of disease flare.
80例前列腺癌患者接受了促黄体生成素释放激素类似物（诺雷德）治疗。10例无转移，激素治疗用作根治性放疗前的诱导治疗。其他患者有转移性疾病，部分患者已接受过某种形式的内分泌治疗。患者每月注射一次诺雷德（3.6毫克）。非转移性肿瘤患者未观察到疾病进展；在有转移的患者中，既往未接受治疗的患者缓解率较高（完全缓解率为14.8%），无进展生存期和总生存期更长。尽管有2例疾病突发，但毒性较轻。
Zotero 插件